Seeking Alpha

More on Valeant (VRX +2.3%) Q1: Swings to net loss of $12.9M from a profit of $6.5M after taking...

More on Valeant (VRX +2.3%) Q1: Swings to net loss of $12.9M from a profit of $6.5M after taking increased provisions for restructuring and acquisition-related costs, and other charges. To buy assets from University Medical Pharmaceuticals, which focuses on skincare, for $64M and milestone payments.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|